This database contains 222 studies, archived under the term: "cognition disorders"
Click here to filter this large number of results.
Detection of cognitive impairment and dementia using the animal fluency test: the DECIDE study
Sebaldt, Rolf,
Dalziel, William,
Massoud, Fadi,
Tanguay, André,
Ward, Rick,
Thabane, Lehana,
Melnyk, Peter,
Landry, Pierre-Alexandre,
Lescrauwaet, Benedicte
Objectives: To evaluate the performance of a one-minute screening test measured against a validated 10-minute screening test for mild cognitive impairment (MCI) in detecting CI in patients aged > or = 65 years with two or more vascular risk factors (VRF).; Methods: Patients (n=1523) aged 65 years or older without documented CI symptoms or dementia […]
A multicenter, double-blind, placebo-controlled trial of the PDE9A inhibitor, PF-04447943, in Alzheimer’s disease
Schwam, Elias M.,
Nicholas, Timothy,
Chew, Robert,
Billing, Clare B.,
Davidson, Wendy,
Ambrose, Darlene,
Altstiel, Larry D.
Background: PF-04447943 is a potent, selective phosphodiesterase 9A (PDE9A) inhibitor that elevates guanoscine 3′,5′ – cyclic monophosphate (cGMP) in brain and cerebrospinal fluid. PDE9A inhibition enhances synaptic plasticity and improves memory in preclinical cognition models, and prevents decreases in dendritic spine density in transgenic mice that overexpress amyloid precursor protein (APP) leading to high levels […]
Efficacy of a medical food in mild Alzheimer’s disease: A randomized, controlled trial
Scheltens, Philip,
Kamphuis, Patrick J. G. H.,
Verhey, Frans R.J.,
Olde Rikkert, Marcel G. M.,
Wurtman, Richard J.,
Wilkinson, David,
Twisk, Jos W.R.,
Kurz, Alexander
Objective: To investigate the effect of a medical food on cognitive function in people with mild Alzheimer’s disease (AD).; Methods: A total of 225 drug-naïve AD patients participated in this randomized, double-blind controlled trial. Patients were randomized to active product, Souvenaid, or a control drink, taken once-daily for 12 weeks. Primary outcome measures were the […]
Anhedonia and cognitive impairment in Parkinson’s disease: Italian validation of the Snaith-Hamilton Pleasure Scale and its application in the clinical routine practice during the PRIAMO study
Santangelo, G.,
Morgante, L.,
Savica, R.,
Marconi, R.,
Grasso, L.,
Antonini, A.,
De Gaspari, D.,
Ottaviani, D.,
Tiple, D.,
Simoni, L.,
Barone, P.
Objective: To assess the psychometric properties of the Italian version of the Snaith-Hamilton Pleasure Scale (SHAPS) and to study the relationship between anhedonia, depression and cognitive impairment in patients with Parkinson’s disease (PD).; Methods: The SHAPS (14 items) was translated into Italian and pre-tested in a pilot study. Two items evaluating physical anhedonia related to […]
Impact of smoking on cognitive decline in early old age: the Whitehall II cohort study
Sabia, Séverine,
Elbaz, Alexis,
Dugravot, Aline,
Head, Jenny,
Shipley, Martin,
Hagger-Johnson, Gareth,
Kivimaki, Mika,
Singh-Manoux, Archana
Context: Smoking is a possible risk factor for dementia, although its impact may have been underestimated in elderly populations because of the shorter life span of smokers.; Objective: To examine the association between smoking history and cognitive decline in the transition from midlife to old age.; Design: Cohort study.; Setting: The Whitehall II study. The […]
Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer’s disease: analysis of effects of baseline features on treatment response
Sabbagh, Marwan,
Cummings, Jeffrey,
Christensen, Daniel,
Doody, Rachelle,
Farlow, Martin,
Liu, Liang,
Mackell, Joan,
Fain, Randi
Background: Treatment of Alzheimer’s disease with acetylcholinesterase inhibitors can result in symptomatic benefits, but patients often show variable responses. The objective of this post hoc analysis was to investigate relationships between easily identifiable baseline characteristics/demographics and cognitive response in patients treated with either donepezil 23 mg/d or 10 mg/d and to identify factors potentially influencing response.; Methods: […]
The effect of midlife physical activity on structural brain changes in the elderly
Rovio, Suvi,
Spulber, Gabriela,
Nieminen, Lasse J.,
Niskanen, Eini,
Winblad, Bengt,
Tuomilehto, Jaakko,
Nissinen, Aulikki,
Soininen, Hilkka,
Kivipelto, Miia
Physical activity has been associated with decreased dementia risk in recent studies, but the effects for structural brain changes (i.e. white matter lesions (WML) and/or brain atrophy) have remained unclear. The CAIDE participants were a random population-based sample studied in midlife and re-examined on average 21 years later (n=2000). A subpopulation (n=75; 31 control, 23 […]
PRECREST: a phase II prevention and biomarker trial of creatine in at-risk Huntington disease
Rosas, H. D.,
Doros, G.,
Gevorkian, S.,
Malarick, K.,
Reuter, M.,
Coutu, J.-P.,
Triggs, T. D.,
Wilkens, P. J.,
Matson, W.,
Salat, D. H.,
Hersch, S. M.
Objective: To assess the safety and tolerability of high-dose creatine, the feasibility of enrolling premanifest and 50% at-risk subjects in a prevention trial, and the potential of cognitive, imaging, and blood markers.; Methods: Sixty-four eligible consenting participants were randomly allocated (1:1) to 15 g twice daily of creatine monohydrate or placebo for a 6-month double-blind […]
Cognitive assessment of elderly patients in the emergency department: a comparison between standard tools, medical records and physicians’ perception
Rodríguez-Molinero, Alejandro,
López-Diéguez, María,
Pérez Medina, Iñaki,
Tabuenca, Ana I.,
De La Cruz, Juan J.,
Banegas, José R.
Introduction: We evaluated the accuracy of physician recognition of cognitive impairment in elderly patients in emergency departments (ED). In particular, we evaluated the accuracy of the subjective impression of the physician on patients’ cognition (a comparison of the information obtained from the responsible physician with the S-IQCODE, a cognitive impairment screening test), and the accuracy […]